Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
03/2014
03/25/2014CA2612282C Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
03/25/2014CA2607142C Personal care compositions and methods for their use
03/25/2014CA2553199C System for up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the application of fields generated by specific electric and electromagnetic signals
03/25/2014CA2537896C East coast fever vaccine based on ctl-specific schizont antigens
03/25/2014CA2521438C Prion protein binding materials and methods of use
03/25/2014CA2484538C Vectors with modified protease-dependent tropism
03/25/2014CA2474011C Use of the mammalian cytokine, tslp/il-50, for modulating dendritic cell activity and treatment of immune disorders
03/25/2014CA2435000C Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
03/25/2014CA2434672C Sfrp and peptide motifs that interact with sfrp and methods of their use
03/25/2014CA2404448C Genes involved in intestinal inflammatory diseases and use thereof
03/25/2014CA2383642C Anthozoa derived chromophores/fluorophores and methods for using the same
03/25/2014CA2379963C Mammalian cytokines; related reagents
03/25/2014CA2334696C Purification process for production of mannan-binding lectin and an mbl medicinal product
03/20/2014WO2014043594A1 Inhibitors of beta integrin-g protein alpha subunit binding interactions
03/20/2014WO2014043518A1 Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
03/20/2014WO2014043441A1 T cell receptors recognizing mhc class ii-restricted mage-a3
03/20/2014WO2014043344A1 Fibronectin based scaffold domain proteins that bind to myostatin
03/20/2014WO2014042669A1 Antibody evolution immunogens
03/20/2014WO2014042493A1 Novel epitope of ip-10 and antibody to same
03/20/2014WO2014042226A1 Antigen-specific helper t-cell receptor genes
03/20/2014WO2014042148A1 Cancer marker and application thereof
03/20/2014WO2014041526A1 Peptide antagonists of the vasopressin-2 receptor
03/20/2014WO2014041505A1 Cell penetrating peptides
03/20/2014WO2014041444A1 Fungal resistant plants expressing hcp4
03/20/2014WO2014041375A1 Peptide analogues of glucagon and glp1
03/20/2014WO2014041372A1 Lipases, polynucleotides encoding them and their uses
03/20/2014WO2014041327A1 Genetically edited animal
03/20/2014WO2014041231A1 Hydrogel used as an injectable support for application in cell therapy and as a system for the controlled release of drugs
03/20/2014WO2014041195A1 Glucagon analogues
03/20/2014WO2014041189A1 Salmonid alphavirus and uses thereof
03/20/2014WO2014041082A1 Influenza virus
03/20/2014WO2014041035A1 Diagnostic method for detecting an autoimmune disease and related subject-matter
03/20/2014WO2014041026A1 Artificial plant receptors and ligands
03/20/2014WO2014040605A1 New peptides as a monotherapy in malignancy control
03/20/2014WO2014040302A1 Use of pedf-derived polypeptides for treating alopecia and/or hair depigmentation
03/20/2014WO2014040178A1 Trpv3 agonists for the treatment of skin conditions
03/20/2014WO2014040131A1 Stem cell growth factor
03/20/2014WO2014004719A3 Chimeric peptide comprising an extracellular matrix protein together with an|antimicrobial peptide for use as a scaffold in wound dressing
03/20/2014WO2013163567A3 Novel alpha-helical peptidomimetic inhibitors and methods using same
03/20/2014WO2013126746A3 Dll3 modulators and methods of use
03/20/2014WO2012159196A8 Plants having enhanced abiotic stress resistance
03/20/2014WO2012006640A3 Compositions and methods useful in enhancement of memory
03/20/2014WO2012006382A3 Methods for enhanced root nodulation in legumes
03/20/2014WO2009014835A9 Modified toxins
03/20/2014WO2008019491A8 Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
03/20/2014US20140082769 Molecules and methods for inhibition and detection of proteins
03/20/2014US20140082766 Antimicrobial peptides and uses thereof
03/20/2014US20140081008 Scalable Process for Protein Purification
03/20/2014US20140081006 Method for producing mullerian inhibitor substance in plants
03/20/2014US20140081004 Glycosylated specificity exchangers
03/20/2014US20140080997 Novel mite allergen
03/20/2014US20140080765 Novel metalloprotein and process for producing same, and prophylactic or therapeutic agent for corneal and conjunctival diseases comprising said metalloprotein
03/20/2014US20140080757 Glucagon analogues
03/20/2014US20140080208 Adenoviral vector vaccine
03/20/2014US20140080182 Cellulose Binding Domain Variants and Polynucleotides Encoding Same
03/20/2014US20140080178 Polypeptides Having Cellulolytic Enhancing Activity and Polynucleotides Encoding Same
03/20/2014US20140080177 Anticalins
03/20/2014US20140079725 Immune suppressor and its use
03/20/2014US20140079716 Anti-lymphotoxin antibodies
03/20/2014US20140079711 Anti-cd147 antibodies, methods and uses
03/20/2014US20140079709 Immunogenic Composition Comprising Alpha-Hemolysin Oligopeptides
03/20/2014US20140079700 Method for promoting bone growth using activin-actriia antagonists
03/20/2014US20140079698 Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
03/20/2014US20140079683 Multifunctional Cellulase And Hemicellulase
03/20/2014US20140079674 Spider silk proteins and methods for producing spider silk proteins
03/20/2014US20140079668 Targeted interferons demonstrate potent apoptotic and anti-tumor activities
03/20/2014US20140079643 Protein skeletal module which increases the binding affinity and binding specificity of active polypeptides
03/20/2014DE102012108599A1 New peptide containing amino acid sequences and their homologues and polymers and their homologues, useful to inhibit fibril formation of amyloid-beta peptides and to bind aggregated amyloid beta peptides to treat Alzheimers disease
03/20/2014CA2875174A1 Fungal resistant plants expressing hcp4
03/19/2014EP2708554A1 Insulin analogues with an acyl and alkylene glycol moiety
03/19/2014EP2708553A1 Modified fungal cell
03/19/2014EP2708552A1 Influenza virus
03/19/2014EP2708550A1 Preparation method for insulin glargine crystal
03/19/2014EP2708549A2 Improved vaccines and methods for using the same
03/19/2014EP2708238A1 Cytotoxic t cell inducer
03/19/2014EP2708235A1 Peptide antagonists of the vasopressin-2 receptor
03/19/2014EP2707713A2 Glu-glp-1 dual agonist signaling-selective compounds
03/19/2014EP2707495A1 Biochemical markers for cvd risk assessment
03/19/2014EP2707490A1 Plants having enhanced yield-related traits and method for making the same
03/19/2014EP2707480A1 Virus-like particles and process for preparing same
03/19/2014EP2707445A1 Dryable adhesive coating
03/19/2014EP2707395A2 Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
03/19/2014EP2707394A2 Metallodrugs having improved pharmacological properties, and methods of manufacture and use thereof
03/19/2014EP2707393A1 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
03/19/2014EP2707387A1 A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
03/19/2014EP2707386A1 Methods and means for generating microbial disease resistant plants
03/19/2014EP2707385A1 Pre-fusion rsv f antigens
03/19/2014EP2707024A1 Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
03/19/2014EP2707023A2 Compositions and methods for immunization against drug resistant acinetobacter baumannii
03/19/2014EP2707022A1 Molecule for treating an inflammatory disorder
03/19/2014EP2707021A2 Genetically engineered growth factor variants
03/19/2014EP2706836A1 Plants having enhanced yield-related traits and method for making the same
03/19/2014CN103649315A Hypoallergen
03/19/2014CN103649125A Removal of target cells by circulating virus-specific cytotoxic t-cells using MHC class I comprising complexes
03/19/2014CN103649116A Fusion proteins releasing relaxin and uses thereof
03/19/2014CN103649115A Polypeptides
03/19/2014CN103649114A Novel immunoconjugates
03/19/2014CN103649113A Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
03/19/2014CN103649112A Modified laminin and use thereof
03/19/2014CN103649111A Albumin formulation and use
1 ... 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 ... 2916